Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth A Freedberg

Showing results (191-200 of 325) with videos related to

Pageof 33
Sort By:
Plos One|June 7, 2013
Clinical impact and cost-effectiveness of expanded voluntary HIV testing in IndiaKartik K Venkatesh, Jessica E Becker, Nagalingeswaran Kumarasamy, et al.
AIDS Research and Therapy|August 6, 2024
Willingness to trade-off years of life for an HIV cure - an experimental exploration of affective forecastingIlona Fridman, Nir Eyal, Karen A Scherr, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 14, 2007
The cost-effectiveness of antiretroviral therapy for treating HIV disease in the CaribbeanLindsey L Wolf, Paul Ricketts, Kenneth A Freedberg, et al.
AIDS (London, England)|December 22, 2009
Who starts antiretroviral therapy in Durban, South Africa?... not everyone who shouldIngrid V Bassett, Susan Regan, Senica Chetty, et al.
Open Forum Infectious Diseases|March 4, 2015
The Linkage Outcomes of a Large-scale, Rapid Transfer of HIV-infected Patients From Hospital-based to Community-based Clinics in South AfricaChristie Cloete, Susan Regan, Janet Giddy, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 23, 2011
Medication possession ratio: predicting and decreasing loss to follow-up in antiretroviral treatment programs in Côte d'IvoireEugène Messou, Martial Kouakou, Delphine Gabillard, et al.
BMJ Open|January 12, 2024
Virological, serological and clinical outcomes in chronic hepatitis B virus infection: development and validation of the HEPA-B simulation modelAmir M Mohareb, Arthur Y Kim, Anders Boyd, et al.
Plos Medicine|October 28, 2009
Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisalElena Losina, Hapsatou Touré, Lauren M Uhler, et al.
Annals of Internal Medicine|July 22, 2009
When to start antiretroviral therapy in resource-limited settingsRochelle P Walensky, Lindsey L Wolf, Robin Wood, et al.
AIDS (London, England)|October 20, 2011
Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adultsCaroline E Sloan, Karen Champenois, Philippe Choisy, et al.
Pageof 33

Showing results (191-200 of 325) with videos related to

Sort By:
Pageof 33
Plos One|June 7, 2013
Clinical impact and cost-effectiveness of expanded voluntary HIV testing in IndiaKartik K Venkatesh, Jessica E Becker, Nagalingeswaran Kumarasamy, et al.
AIDS Research and Therapy|August 6, 2024
Willingness to trade-off years of life for an HIV cure - an experimental exploration of affective forecastingIlona Fridman, Nir Eyal, Karen A Scherr, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 14, 2007
The cost-effectiveness of antiretroviral therapy for treating HIV disease in the CaribbeanLindsey L Wolf, Paul Ricketts, Kenneth A Freedberg, et al.
AIDS (London, England)|December 22, 2009
Who starts antiretroviral therapy in Durban, South Africa?... not everyone who shouldIngrid V Bassett, Susan Regan, Senica Chetty, et al.
Open Forum Infectious Diseases|March 4, 2015
The Linkage Outcomes of a Large-scale, Rapid Transfer of HIV-infected Patients From Hospital-based to Community-based Clinics in South AfricaChristie Cloete, Susan Regan, Janet Giddy, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 23, 2011
Medication possession ratio: predicting and decreasing loss to follow-up in antiretroviral treatment programs in Côte d'IvoireEugène Messou, Martial Kouakou, Delphine Gabillard, et al.
BMJ Open|January 12, 2024
Virological, serological and clinical outcomes in chronic hepatitis B virus infection: development and validation of the HEPA-B simulation modelAmir M Mohareb, Arthur Y Kim, Anders Boyd, et al.
Plos Medicine|October 28, 2009
Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisalElena Losina, Hapsatou Touré, Lauren M Uhler, et al.
Annals of Internal Medicine|July 22, 2009
When to start antiretroviral therapy in resource-limited settingsRochelle P Walensky, Lindsey L Wolf, Robin Wood, et al.
AIDS (London, England)|October 20, 2011
Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adultsCaroline E Sloan, Karen Champenois, Philippe Choisy, et al.
Pageof 33